|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
FDA vs. Drug Ads: Cut the Kids and Dogs, Spell Out Side Effects
|
Arlene Weintraub |
02/06/12 |
National
|
|
Affymax Prepares to Mount Challenge to Amgen Anemia Drug Monopoly
|
Luke Timmerman |
01/25/12 |
San Francisco
|
|
Onyx, Bayer’s Next Cancer Drug Shows Slim Survival Edge
|
Luke Timmerman |
01/17/12 |
San Francisco
|
|
Five Myths You’ll Hear This Week at the JP Morgan Healthcare Conference
|
Luke Timmerman |
01/09/12 |
National
|
|
Alnylam Gets First Hint of Effectiveness for RNAi Cholesterol-Lowering Drug
|
Luke Timmerman |
01/04/12 |
Boston
|
|
Momenta, Baxter Team Up on Biosimilars
|
Erin Kutz |
12/23/11 |
Boston
|
|
Millennium, Metamark, Amgen, & More Boston Life Sciences Headlines
|
Erin Kutz |
12/23/11 |
Boston
|
|
The Year in Seattle Biotech: Lots of Acquisitions, Few New Startups
|
Luke Timmerman |
12/22/11 |
Seattle
|
|
MIT-Born Enumeral Advances Human-Based Method for Hunting Drugs
|
Arlene Weintraub |
12/20/11 |
New York
|
|
Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs
|
Luke Timmerman |
12/19/11 |
National
|
|
Amgen CEO Kevin Sharer’s Report Card: C
|
Luke Timmerman |
12/19/11 |
National
|
|
Affymax Passes FDA Panel Scrutiny, Looks to Challenge Amgen Anemia Drug
|
Luke Timmerman |
12/07/11 |
San Francisco
|
|
Affymax Shares Climb As FDA Considers Wider Use for Anemia Drug
|
Luke Timmerman |
12/05/11 |
San Francisco
|
|
My Immunex Remembrance: Getting Scooped on the Biggest Biotech Story of 2001
|
Luke Timmerman |
11/18/11 |
Seattle
|
|
Affymax Gears Up for its Make-or-Break Moment, As Anemia Drug Faces FDA Scrutiny
|
Luke Timmerman |
11/17/11 |
San Francisco
|
|
Biopharmaceuticals: Nothing Compares to You
|
Stewart Lyman |
11/17/11 |
National
|
|
The Immunex Impact: A Trivia Quiz
|
Luke Timmerman |
11/15/11 |
Seattle
|
|
Editor’s Picks: Xconomy Boston’s Top 20 Stories of the Third Quarter
|
Gregory T. Huang |
10/28/11 |
Boston
|
|
Amgen Cuts 70 Washington Jobs, Hutch Spins Off Blaze Bioscience, Henney Enters the Hall, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/20/11 |
Seattle
|
|
Amgen Confirms 380 Layoffs in R&D; Cuts Coming to Seattle, SF, Boston
|
Luke Timmerman |
10/19/11 |
National
|
|
Got Some Immunex Memorabilia in the Closet? Break it Out at the Immunex Impact Dec. 1
|
Luke Timmerman |
10/19/11 |
Seattle
|
|
NextBio Sees Growth in Next Market: Physicians Seeking Help Interpreting Individual Genomes
|
Luke Timmerman |
10/18/11 |
San Francisco
|
|
Amgen Mulls R&D Cuts, Thong Le Named WBBA Chairman, NanoString’s Version 2.0, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/13/11 |
Seattle
|
|
Amgen Looking to Improve Focus and “Re-allocate Resources” for R&D, Say More Oct. 24
|
Luke Timmerman |
10/12/11 |
National
|
|
Merck Fine-Tunes Biosimilars Strategy as FDA Guidelines Loom
|
Arlene Weintraub |
10/05/11 |
New York
|
|
Crescendo Bioscience Nabs $56M to Help Personalize Rheumatoid Arthritis Therapy
|
Luke Timmerman |
09/08/11 |
San Francisco
|
|
Fearless Fantasy Football, Uh, I Mean Biotech, Predictions for the Season Ahead
|
Luke Timmerman |
09/06/11 |
National
|
|
Jennerex Shows that Unorthodox Cancer-Fighting Virus Can be Delivered the Usual Way
|
Luke Timmerman |
08/31/11 |
San Francisco
|
|
Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies
|
Luke Timmerman |
08/29/11 |
Seattle
|
|
Acceleron, Celgene Take Aim at Amgen’s Multibillion-Dollar Anemia Market
|
Luke Timmerman |
08/05/11 |
Boston
|
|
Page 1 of
9 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.